21 May 2013
Keywords: lintuzumab, ph, iib, amd, trial, completes, enrollment
Article | 02 March 2009
US drug developer Seattle Genetics has completed patient enrollment in a Phase IIb trial of lintuzumab (SGN-33) in combination with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 December 2008
15 December 2008
20 May 2013
© 2013 thepharmaletter.com